Harvard Bioscience, Inc.
HBIO
$0.76
$0.011.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 74.36% | 22.04% | -972.43% | 100.99% | -287.57% |
| Total Depreciation and Amortization | -27.05% | -10.27% | -7.07% | -0.96% | 2.02% |
| Total Amortization of Deferred Charges | 301.12% | 200.00% | 87.14% | 40.00% | 27.14% |
| Total Other Non-Cash Items | -77.49% | -76.40% | 1,792.36% | -76.55% | 849.07% |
| Change in Net Operating Assets | -45.08% | 276.74% | 105.62% | -124.82% | -85.29% |
| Cash from Operations | 228.74% | 425.65% | 112.83% | -59.91% | -119.31% |
| Capital Expenditure | 76.48% | 89.12% | 20.47% | 63.73% | -305.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 38.96% | -111.29% | -140.48% | 28.57% | -25.54% |
| Cash from Investing | 68.68% | -150.87% | -203.56% | 56.08% | -177.06% |
| Total Debt Issued | -- | -- | -- | -100.00% | 225.00% |
| Total Debt Repaid | 0.00% | 67.21% | 71.62% | 69.23% | 73.33% |
| Issuance of Common Stock | -100.00% | -75.66% | -- | -21.84% | -- |
| Repurchase of Common Stock | -- | 100.00% | -59.57% | 75.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -57.76% | -- | -- | -- | -- |
| Cash from Financing | -160.74% | -810.73% | -14.12% | 67.03% | 176.51% |
| Foreign Exchange rate Adjustments | -122.43% | 15,700.00% | 324.50% | -98.36% | 290.72% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -219.96% | 1,015.94% | 5,235.71% | 56.39% | -48.72% |